HER-2/neu and CD117 (C-kit) overexpression in hepatocellular and pancreatic carcinoma

Anil Potti, Apar Kishor P Ganti, Ketki K Tendulkar, Sidharth Chitajallu, Kaley Sholes, Michael Koch, Steven Kargas

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Background: Hepatocellular carcinoma has an overall 5-year survival of less than 5%. Similarly, pancreatic cancer has a mortality:incidence ratio of 0.99. The aim of this study was to determine the prevalence of HER-2/neu and c-kit (CD117) overexpression and to identify a possible predictive role in patients with these two malignancies. Materials and Methods: We performed a retrospective study on archival specimens of subjects with hepatocellular and pancreatic carcinoma. HER-2/neu and CD117 overexpression were evaluated by immunohistochemistry. Results: Thirty-three patients with pancreatic carcinoma and 25 patients with hepatocellular carcinoma were identified. The mean age was 71.7 years for patients with pancreatic carcinoma and 66 years for patients with hepatocellular carcinoma. Two patients with hepatocellular carcinoma and none with pancreatic cancer overexpressed HER-2/neu, while 2 patients with pancreatic carcinoma and 1 patient with hepatocellular carcinoma overexpressed CD117. Conclusion: HER-2/neu and CD117 are not significantly overexpressed in either cancer. There appears to be no role for the use of trastuzumab in either malignancy. Similarly, while there appears to be no role for tyrosine kinase inhibitors in the treatment of hepatocellular carcinoma, further larger studies are necessary in pancreatic adenocarcinoma.

Original languageEnglish (US)
Pages (from-to)2671-2674
Number of pages4
JournalAnticancer Research
Volume23
Issue number3 B
StatePublished - May 1 2003
Externally publishedYes

Fingerprint

Hepatocellular Carcinoma
Pancreatic Neoplasms
Neoplasms
Pancreatic Carcinoma
Protein-Tyrosine Kinases
Adenocarcinoma
Retrospective Studies
Immunohistochemistry
Survival
Mortality
Incidence

Keywords

  • Adenocarcinoma of the pancreas
  • C-kit
  • HER-2/neu
  • Hepatocellular carcinoma

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Potti, A., Ganti, A. K. P., Tendulkar, K. K., Chitajallu, S., Sholes, K., Koch, M., & Kargas, S. (2003). HER-2/neu and CD117 (C-kit) overexpression in hepatocellular and pancreatic carcinoma. Anticancer Research, 23(3 B), 2671-2674.

HER-2/neu and CD117 (C-kit) overexpression in hepatocellular and pancreatic carcinoma. / Potti, Anil; Ganti, Apar Kishor P; Tendulkar, Ketki K; Chitajallu, Sidharth; Sholes, Kaley; Koch, Michael; Kargas, Steven.

In: Anticancer Research, Vol. 23, No. 3 B, 01.05.2003, p. 2671-2674.

Research output: Contribution to journalArticle

Potti, A, Ganti, AKP, Tendulkar, KK, Chitajallu, S, Sholes, K, Koch, M & Kargas, S 2003, 'HER-2/neu and CD117 (C-kit) overexpression in hepatocellular and pancreatic carcinoma', Anticancer Research, vol. 23, no. 3 B, pp. 2671-2674.
Potti, Anil ; Ganti, Apar Kishor P ; Tendulkar, Ketki K ; Chitajallu, Sidharth ; Sholes, Kaley ; Koch, Michael ; Kargas, Steven. / HER-2/neu and CD117 (C-kit) overexpression in hepatocellular and pancreatic carcinoma. In: Anticancer Research. 2003 ; Vol. 23, No. 3 B. pp. 2671-2674.
@article{d89a28c1b2584951b9349d2d847e1bf4,
title = "HER-2/neu and CD117 (C-kit) overexpression in hepatocellular and pancreatic carcinoma",
abstract = "Background: Hepatocellular carcinoma has an overall 5-year survival of less than 5{\%}. Similarly, pancreatic cancer has a mortality:incidence ratio of 0.99. The aim of this study was to determine the prevalence of HER-2/neu and c-kit (CD117) overexpression and to identify a possible predictive role in patients with these two malignancies. Materials and Methods: We performed a retrospective study on archival specimens of subjects with hepatocellular and pancreatic carcinoma. HER-2/neu and CD117 overexpression were evaluated by immunohistochemistry. Results: Thirty-three patients with pancreatic carcinoma and 25 patients with hepatocellular carcinoma were identified. The mean age was 71.7 years for patients with pancreatic carcinoma and 66 years for patients with hepatocellular carcinoma. Two patients with hepatocellular carcinoma and none with pancreatic cancer overexpressed HER-2/neu, while 2 patients with pancreatic carcinoma and 1 patient with hepatocellular carcinoma overexpressed CD117. Conclusion: HER-2/neu and CD117 are not significantly overexpressed in either cancer. There appears to be no role for the use of trastuzumab in either malignancy. Similarly, while there appears to be no role for tyrosine kinase inhibitors in the treatment of hepatocellular carcinoma, further larger studies are necessary in pancreatic adenocarcinoma.",
keywords = "Adenocarcinoma of the pancreas, C-kit, HER-2/neu, Hepatocellular carcinoma",
author = "Anil Potti and Ganti, {Apar Kishor P} and Tendulkar, {Ketki K} and Sidharth Chitajallu and Kaley Sholes and Michael Koch and Steven Kargas",
year = "2003",
month = "5",
day = "1",
language = "English (US)",
volume = "23",
pages = "2671--2674",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "3 B",

}

TY - JOUR

T1 - HER-2/neu and CD117 (C-kit) overexpression in hepatocellular and pancreatic carcinoma

AU - Potti, Anil

AU - Ganti, Apar Kishor P

AU - Tendulkar, Ketki K

AU - Chitajallu, Sidharth

AU - Sholes, Kaley

AU - Koch, Michael

AU - Kargas, Steven

PY - 2003/5/1

Y1 - 2003/5/1

N2 - Background: Hepatocellular carcinoma has an overall 5-year survival of less than 5%. Similarly, pancreatic cancer has a mortality:incidence ratio of 0.99. The aim of this study was to determine the prevalence of HER-2/neu and c-kit (CD117) overexpression and to identify a possible predictive role in patients with these two malignancies. Materials and Methods: We performed a retrospective study on archival specimens of subjects with hepatocellular and pancreatic carcinoma. HER-2/neu and CD117 overexpression were evaluated by immunohistochemistry. Results: Thirty-three patients with pancreatic carcinoma and 25 patients with hepatocellular carcinoma were identified. The mean age was 71.7 years for patients with pancreatic carcinoma and 66 years for patients with hepatocellular carcinoma. Two patients with hepatocellular carcinoma and none with pancreatic cancer overexpressed HER-2/neu, while 2 patients with pancreatic carcinoma and 1 patient with hepatocellular carcinoma overexpressed CD117. Conclusion: HER-2/neu and CD117 are not significantly overexpressed in either cancer. There appears to be no role for the use of trastuzumab in either malignancy. Similarly, while there appears to be no role for tyrosine kinase inhibitors in the treatment of hepatocellular carcinoma, further larger studies are necessary in pancreatic adenocarcinoma.

AB - Background: Hepatocellular carcinoma has an overall 5-year survival of less than 5%. Similarly, pancreatic cancer has a mortality:incidence ratio of 0.99. The aim of this study was to determine the prevalence of HER-2/neu and c-kit (CD117) overexpression and to identify a possible predictive role in patients with these two malignancies. Materials and Methods: We performed a retrospective study on archival specimens of subjects with hepatocellular and pancreatic carcinoma. HER-2/neu and CD117 overexpression were evaluated by immunohistochemistry. Results: Thirty-three patients with pancreatic carcinoma and 25 patients with hepatocellular carcinoma were identified. The mean age was 71.7 years for patients with pancreatic carcinoma and 66 years for patients with hepatocellular carcinoma. Two patients with hepatocellular carcinoma and none with pancreatic cancer overexpressed HER-2/neu, while 2 patients with pancreatic carcinoma and 1 patient with hepatocellular carcinoma overexpressed CD117. Conclusion: HER-2/neu and CD117 are not significantly overexpressed in either cancer. There appears to be no role for the use of trastuzumab in either malignancy. Similarly, while there appears to be no role for tyrosine kinase inhibitors in the treatment of hepatocellular carcinoma, further larger studies are necessary in pancreatic adenocarcinoma.

KW - Adenocarcinoma of the pancreas

KW - C-kit

KW - HER-2/neu

KW - Hepatocellular carcinoma

UR - http://www.scopus.com/inward/record.url?scp=0042807493&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0042807493&partnerID=8YFLogxK

M3 - Article

VL - 23

SP - 2671

EP - 2674

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 3 B

ER -